4 recruiting, 3 completed, 2 unknown, 1 terminated. 5 Phase 2, 2 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 2, Completed 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Not applicable | 1 | Completed 1 |
Follow Relapsing Polychondritis: new trials by email Literature Review of Relapsing Polychondritis trials Research Report on Relapsing Polychondritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pragmatic, Open-Label Study to Pilot Evaluation for Clinical Trials in Relapsing Polychondritis Methotrexate (MTX), Azathioprine (AZA), Adalimumab - Relapsing Polychondritis | Phase 2 | Recruiting | University of Pennsylvania | 20 | 2025-11-11 | 2026-09-02 |
| Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis Upadacitinib, corticosteroids and immunosuppressants - Relapsing Polychondritis | Phase 1 / Phase 2 | Recruiting | Peking University People's Hospital | 30 | 2024-11-15 | 2025-03-12 |
| Pediatric Relapsing Polychondritis : Diagnosis and Management in a French Retrospective Study Relapsing Polychondritis | Unknown | University Hospital, Strasbourg, France | 20 | 2023-02-18 | 2023-11-02 | |
| Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis Rituximab, Infliximab, Tocilizumab - Giant Cell Arteritis, Takayasu Arteritis | Phase 2 | Terminated | Cambridge University Hospitals NHS Foundation Trust | 22 | 2021-07-14 | 2025-06-17 |
| Longitudinal Study for Relapsing Polychondritis Relapsing Polychondritis, Vasculitis | Recruiting | University of Pennsylvania | 100 | 2021-02-26 | 2026-01-23 | |
| Low-dose Recombinant Human IL-2 for the Treatment of Relapsing Polychondritis Interleukin-2 - Relapsing Polychondritis | Phase 2 | Completed | Peking University People's Hospital | 10 | 2019-11-01 | 2024-02-26 |
| PatientSpot Formerly Known as ArthritisPower Rheumatoid Arthritis, Ankylosing Spondylitis | Unknown | Global Healthy Living Foundation | 40000 | 2015-04-01 | 2023-12-13 | |
| Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis Takayasu's Arteritis, Giant Cell Arteritis | Recruiting | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 4000 | 2014-09-29 | 2026-10-29 | |
| Study on the Safety of Abatacept in Relapsing Polychondritis Abatacept - Relapsing Polychondritis | Phase 1 | Completed | Benaroya Research Institute | 4 | 2011-01-01 | 2012-08-07 |
| Tocilizumab for Relapsing Polychondritis Tocilizumab - Relapsing Polychondritis | Phase 2 | Withdrawn | McMaster Children's Hospital | 2010-05-01 | 2014-05-13 | |
| Single Patient Study to Treat Relapsing Polychondritis With Tocilizumab Tocilizumab - Relapsing Polychondritis | Not applicable | Completed | Children's Hospital of Eastern Ontario | 1 | 2010-01-01 | 2021-03-03 |
Polychondritis, Relapsing (11) · Giant Cell Arteritis (3) · Vasculitis (3) · Polyarteritis Nodosa (2) · Takayasu Arteritis (2) · Alopecia (1) · Alzheimer Disease (1) · Amyotrophic Lateral Sclerosis (1) · Angina, Unstable (1) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Arrhythmias, Cardiac (1) · Arthritis, Juvenile (1) · Arthritis, Psoriatic (1) · Arthritis, Rheumatoid (1) · Asthma (1)
Cartilage Diseases (11) · Connective Tissue Diseases (11) · Musculoskeletal Diseases (11) · Skin and Connective Tissue Diseases (11) · Cardiovascular Diseases (5) · Vascular Diseases (5) · Arteritis (3) · Autoimmune Diseases (3) · Autoimmune Diseases of the Nervous System (3) · Brain Diseases (3) · Central Nervous System Diseases (3) · Cerebrovascular Disorders (3) · Immune System Diseases (3) · Nervous System Diseases (3) · Pathologic Processes (3)
tocilizumab (4) · Infliximab (2) · Abatacept (1) · Adalimumab (1) · Adrenal Cortex Hormones (1) · Azathioprine (1) · Immunosuppressive Agents (1) · Interleukin-2 (1) · Methotrexate (1) · Rituximab (1) · aldesleukin (1) · upadacitinib (1)
Peking University People's Hospital (2) · University of Pennsylvania (2) · Benaroya Research Institute (1) · Cambridge University Hospitals NHS Foundation Trust (1) · Children's Hospital of Eastern Ontario (1) · Global Healthy Living Foundation (1) · McMaster Children's Hospital (1) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1) · University Hospital, Strasbourg, France (1)
United States (5) · Canada (2) · China (2) · France (1) · United Kingdom (1)
Shubhasree Banerjee, MD (2) · David Jayne (1) · Johannes Roth, MD (1) · Li Zhanguo (1) · Peter C Grayson, M.D. (1) · Peter Merkel, MD, MPH (1) · Zhanguo Li (1)